Posting of Annual Report and AGM Notice

Verona Pharma plc ("Verona Pharma" or the "Company") Posting of Annual Report and AGM Notice 19 May 2014, Cardiff - Verona Pharma plc (AIM: VRP) announces that theCompany's annual report and accounts for the year ended 31 December 2013 andthe 2014 Annual General Meeting notice were today posted to shareholders andwill shortly be available for download at the Company's websitewww.veronapharma.com. -Ends- For more information, please contact: Verona Pharma plc Tel: 020 7863 3300Jan-Anders Karlsson, CEORichard Bungay, CFO WH Ireland Limited (NOMAD) Tel: 020 7220 1666Chris FieldingNick Field Notes to Editors About Verona Pharma plc Verona Pharma is developing "first-in-class" drugs to treat respiratorydisease, such as COPD, asthma and chronic, severe cough. The Company has threedrug programmes, two of which are in Phase II. The lead programme, RPL554, isan innovative dual phosphodiesterase (PDE) 3 and 4 inhibitor with bothbronchodilator and anti-inflammatory properties. VRP700 is an innovativeproduct for suppressing chronic, severe cough in patients with underlying lungdisease. In its third programme, Verona Pharma is investigating novelanti-inflammatory molecules, called NAIPs, for a wide range of respiratory andinflammatory diseases.